A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.
- Mechanism
- Curator reviewed
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
- Primary indication
- For use as a female contraceptive.Curator reviewed
- Code names
- AP1081
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with AP1081, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account